September 13, 2018 / 3:41 PM / 11 days ago

BRIEF-Genentech Says FDA Approves Subcutaneous Formulation Of Actemra For Use In Active Systemic Juvenile Idiopathic Arthritis

Sept 13 (Reuters) - Genentech:

* FDA APPROVES SUBCUTANEOUS FORMULATION OF ACTEMRA FOR USE IN ACTIVE SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA), A RARE FORM OF JUVENILE ARTHRITIS

* GENENTECH SAYS FDA'S APPROVAL OF SUBCUTANEOUS FORMULATION OF ACTEMRA IS BASED ON DATA FROM JIGSAW-118 STUDY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below